Population PK–PD analyses of CD25 occupancy, CD56^bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis

Abstract

Robust PK-PD models of CD25 occupancy, CD56^bright NK cell expansion and Treg reduction by daclizumab HYP were developed to characterize its key pharmacodynamic effects in the target patient population.